Navigation Links
New review outlines screening strategies for osteoporosis in young adults

Nyon, Switzerland June 15, 2012 -- Much of the research defining osteoporosis and fracture risk has focused on older adults, i.e. postmenopausal women and men over the age of 50. While older adults are at highest risk of osteoporosis and related fractures, the disease can also affect younger adults between 20 and 50 years of age. However, the diagnosis and management of osteoporosis in young adults is complicated by special challenges, including a complex pathophysiology and the related fact that there is no clear definition of osteoporosis, or of intervention thresholds, in this age group.

An International Osteoporosis Foundation (IOF) scientific working group has now published a review which outlines the pathophysiology, diagnosis and management of osteoporosis in young adults, providing a clear screening strategy that includes the use of clinical and laboratory exams.

Dr. Serge Ferrari of the University of Geneva andchair of the IOF Working Group on Osteoporosis Pathophysiology, explains the diagnostic challenge faced by clinicians, "Low bone mass in this age group may not necessarily represent a pathological condition, but result instead from low peak bone mass in relation to body size, late puberty, or genetic and environmental background."

On the other hand, there are young adults who may truly have osteoporosis with bone fragility at a young age. This may result from altered bone modelling and/or remodelling during growth or later due to a chronic disorder or a genetic or idiopathic condition. Typical examples would be inflammatory bowel diseases, particularly Crohn's disease. These diseases impair bone mass gain and/or accelerate bone loss because of malabsorption and poor nutrient intake. In addition, low levels of physical activity, secondary amenorrhea, and in many cases the effects of corticosteroid treatment, can have an impact on bone mass.

Distinguishing between these two situations can be all the more difficult because up to 30% of young women and 50% of young men have had fractures during childhood and adolescence, usually traumatic. These are not necessarily associated with skeletal fragility.

An apparently low areal bone mineral density (T-score < -2.5 at spine or hip by DXA) must be interpreted with caution in young adults of small body size (constitutionally lean) and/or stunted growth. Inaccurate 'diagnosis' of osteoporosis in young subjects can lead to anxiety, unnecessary drug prescriptions, and in some countries potential restrictions of insurance coverage. Individuals with low bone mass, although possibly deserving investigation depending on the context (for instance to rule out vitamin D deficiency) should not automatically be classified as osteoporotic. This diagnosis only applies when there is evidence of skeletal fragility.

Nevertheless, a truly low BMD and/or unusual fractures (such as low-trauma, multiple and vertebral) should prompt investigation for secondary causes of osteoporosis. Careful medical history, clinical and laboratory investigations can reveal an underlying disease that requires specific medical intervention, which in turn will improve bone mass. Bisphosphonates may improve BMD in young subjects with osteoporosis due to various disorders, however the evidence is scarce so far and there are no data on their anti-fracture efficacy. In any case, the indications and duration of anti-resorptive treatment in the young should be as restrictive as possible, particularly in the absence of secondary causes, multiple and/or fragility (vertebral) fractures, and high bone turnover accompanied by documented bone loss.

Professor Cyrus Cooper, chair of the IOF Committee of Scientific Advisors, concluded, "This review will be of assistance to clinicians managing this important problem. The clinical relevance of low bone mineral density in young adults is less well understood than is the case in postmenopausal women and older men. Furthermore, many treatment modalities licensed for use in postmenopausal osteoporosis have not been carefully evaluated in younger adults. Clear guidance as to the interpretation of BMD and the appropriate use of treatments is therefore most timely."

Contact: L. Misteli
International Osteoporosis Foundation

Related biology news :

1. New peer-reviewed journal on big data launching in Fall 2012
2. Research4Life greatly expands peer-reviewed research available to developing world
3. UH makes Princeton Reviews Green List 3 years in a row
4. Agricultural expert outlines path for developing nations to double food production, meet 2050 demand
5. New drug-screening method yields long-sought anti-HIV compounds
6. New screening technique yields elusive compounds to block immune-regulating enzyme
7. Trial seeks improved lung-cancer screening by combining imaging and biomarkers
8. New clinical trial explores novel noninvasive colon cancer screening test
9. New heart repair strategies discussed at UH lecture May 15
10. Bowman provides strategies to engage public with climate change solutions
11. Progress in Osteoporosis re-launched with new design, now invites commentary
Post Your Comments:
(Date:10/29/2015)... Va. , Oct. 29, 2015 Daon, ... today that it has released a new version of ... customers in North America have ... IdentityX v4.0 also includes a FIDO UAF certified ... are already preparing to activate FIDO features. These customers ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
Breaking Biology Technology: